ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselCabaletta Bio GmbH
Cabaletta Bio GmbH Logo
Verified· 2 sources

Cabaletta Bio GmbH

Summary

About the company

Cabaletta Bio GmbH is a clinical‑stage biotechnology company developing engineered T cell therapies for autoimmune diseases. It applies the Cabaletta Approach to B cell Ablation (CABA®) platform and is advancing rese‑cel, a fully human CD19‑CAR T candidate, in RESET™ Phase 1/2 trials to evaluate transient B‑cell depletion as a means to reset the immune system in conditions such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Industry:Pharmaceutical Industry
✓ Offered3
Development of T-cell therapies for autoimmune diseases
Development of engineered T cell therapies and Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) for the treatment of autoimmune diseases with B-cell involvement.
Rese-cel
Investigational fully human CD19 CAR T cell therapy with a 4-1BB co-stimulation domain, as a single-dose infusion for systemic lupus, myositis, systemic sclerosis, gMG and pemphigus vulgaris in clinical development.
Clinical Phase 1/2 trials within the RESET programme
Phase 1/2 clinical trials in lupus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, including RESET-SLE, RESET-Myositis, RESET-SSc, RESET-MG and RESET-PV.

Knowledge

No knowledge articles yet

Once Cabaletta Bio GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Cabaletta Bio GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Cabaletta Bio GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Cabaletta Bio GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 70
4057 Basel

At a glance

Legal form
Limited Liability Company
UID
CHE-180.349.852
Founded
2024 · 2 years
Last commercial register change
October 1, 2025
Employees
21 to 50

Similar companies

TT
TOLREMO therapeutics AG
Basel
MP
Mepha Pharma AG
Basel
ST
Synendos Therapeutics AG
Basel
TT
TargImmune Therapeutics AG
Basel